Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination (Q47977838)

7 February 2018

title

Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination (English)

1 reference

7 February 2018

author name string

Breathnach CC

series ordinal

1

1 reference

7 February 2018

Rudersdorf R

series ordinal

2

1 reference

7 February 2018

Lunn DP

series ordinal

3

1 reference

7 February 2018

publication date

1 April 2004

1 reference

7 February 2018

Veterinary Immunology and Immunopathology

published in

1 reference

7 February 2018

volume

98

1 reference

7 February 2018

issue

3-4

1 reference

7 February 2018

page(s)

127-136

1 reference

7 February 2018

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Duration of circulating antibody and immunity following infection with equine influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Occurrence of infectious upper respiratory tract disease and response to vaccination in horses on six sentinel premises in northern Colorado.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Immunogenicity of a recombinant MVA and a DNA vaccine for Japanese encephalitis virus in swine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Immunity to equine influenza: relationship of vaccine-induced antibody in young Thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

A practical approach to genetic screening for influenza virus variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2003.11.004

10.1016/J.VETIMM.2003.11.004

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

release_ommp4ra2fjhvlcvl4cwc4mlehq

Fatcat ID

0 references

PubMed ID

15010222

1 reference

7 February 2018